• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP NEWS SCAN: COVID-19 antibodies in Geneva; Low global flu levels

Shiloh

Editor, Senior Moderator
Source: https://www.cidrap.umn.edu/news-perspective/2020/06/news-scan-jun-12-2020

News Scan for Jun 12, 2020
COVID-19 antibodies in Geneva; Low global flu levels
Filed Under:
COVID-19; Influenza, General


Study: At least 11% of Geneva’s population has antibodies to SARS-CoV2

A new study in The Lancet shows that the population prevalence of antibodies to SARS-CoV2, the virus that causes COVID-19, grew in Geneva, Switzerland, in April from 5% to 11%.
"At what appears to be the tail end of the first wave of the pandemic in Switzerland, about one in ten people have developed detectable antibodies against SARS-CoV-2, despite the fact that it was one of the more heavily affected areas in Europe," the authors of the study said.
The findings come from the Swiss SEROCoV-POP study, which will conduct serosurveillance in Geneva for 12 weeks. The initial data were collected among 2,766 participants from 1,339 households, between Apr 6 and May 9. In the first week, seroprevalence of antibodies was 4.8%, but by the fifth week it rose to 10.8%. Children ages 5 to 9 years and adults older than 65 were less likely to be seropositive than adults ages 20 to 49.
"After accounting for the time to seroconversion, we estimated that for every reported confirmed case, there were 11.6 infections in the community," the authors wrote.
This means the vast majority of Geneva's population is still at risk of COVID-19 infections, despite a high documented case rate of 10.3 per 1,000 inhabitants, with 5,160 cases and 266 deaths as of May 9 among 500,000 city inhabitants.
Jun 12 Lancet study

Global flu activity lower than expected, Southern Hemisphere quiet

Global flu activity is lower than expected for this time of year, the World Health Organization (WHO) said today, adding a caveat that its information should be interpreted with caution because of possible influences of COVID-19 activity and distancing measures.
In temperate Northern Hemisphere countries, flu has returned to interseasonal levels, and in the Southern Hemisphere, which typically sees levels starting to rise in May, the flu season hasn't started yet.
Some countries in the Caribbean and Central America are reporting increases in severe acute respiratory infection (SARI) activity, such as Costa Rica, though many areas are experiencing rises in COVID-19 cases. In Western Asia, SARI levels rose in Azerbaijan, coinciding with increased COVID-19 activity.
Globally, of flu samples tested in the second half of May, 68.9% were influenza A, and, of the subtyped influenza A viruses, 66.7% were 2009 H1N1.
Jun 12 WHO global flu update
 
Back
Top Bottom